Published in Genes Dev on December 01, 2011
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell (2012) 2.61
Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol (2013) 2.58
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med (2016) 2.27
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nat Cell Biol (2016) 2.20
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell (2014) 2.00
Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 1.95
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ (2013) 1.60
Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle (2012) 1.54
Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol (2013) 1.54
Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. J Exp Med (2016) 1.46
The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med (2015) 1.44
Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci (2012) 1.32
mTOR regulates phagosome and entotic vacuole fission. Mol Biol Cell (2013) 1.22
Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol (2015) 1.22
Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med (2013) 1.21
Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol (2014) 1.19
Cathepsin B as a cancer target. Expert Opin Ther Targets (2013) 1.19
Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc Natl Acad Sci U S A (2013) 1.16
microRNA-mediated regulation of the tumor microenvironment. Cell Cycle (2013) 1.14
New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med (2015) 1.12
Myeloid cells in tumor inflammation. Vasc Cell (2012) 1.12
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer (2014) 1.03
M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer (2015) 1.01
An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity. Cell Adh Migr (2012) 0.99
Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization. Mol Cancer (2014) 0.98
Acid-mediated tumor proteolysis: contribution of cysteine cathepsins. Neoplasia (2013) 0.96
Clinical and biological implications of the tumor microenvironment. Cancer Microenviron (2012) 0.95
Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res (2013) 0.93
The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92
Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene (2013) 0.92
Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell Death Differ (2015) 0.92
Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation. Oncotarget (2014) 0.92
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol (2016) 0.91
Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization. Cancer Microenviron (2014) 0.90
Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer (2015) 0.89
Triptolide induces lysosomal-mediated programmed cell death in MCF-7 breast cancer cells. Int J Womens Health (2013) 0.88
Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Res (2015) 0.88
Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev (2013) 0.87
Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target. Front Pharmacol (2012) 0.86
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. Onco Targets Ther (2016) 0.86
Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase. Oncoimmunology (2013) 0.85
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer (2015) 0.85
Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment. FASEB J (2012) 0.84
A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression. Oncogene (2015) 0.84
Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy. PLoS One (2012) 0.84
The Multifaceted Role of Perivascular Macrophages in Tumors. Cancer Cell (2016) 0.84
Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers. Oncotarget (2015) 0.84
A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells. Br J Cancer (2013) 0.83
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. Cancer Res (2016) 0.83
The impact of chemotherapy and radiation therapy on the remodeling of acellular dermal matrices in staged, prosthetic breast reconstruction. Plast Reconstr Surg (2015) 0.82
miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer. Front Oncol (2014) 0.82
Microenvironment-mediated resistance to anticancer therapies. Cell Res (2012) 0.82
STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody. Nat Commun (2015) 0.81
Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes. Front Chem (2015) 0.80
Design of Protease Activated Optical Contrast Agents That Exploit a Latent Lysosomotropic Effect for Use in Fluorescence-Guided Surgery. ACS Chem Biol (2015) 0.79
Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer (2015) 0.79
M6P/IGF2R modulates the invasiveness of liver cells via its capacity to bind mannose 6-phosphate residues. J Hepatol (2012) 0.79
Tumour progression and metastasis. Ecancermedicalscience (2016) 0.79
Targeting Cathepsin B for Cancer Therapies. Horiz Cancer Res (2015) 0.78
Myeloid Cells as Targets for Therapy in Solid Tumors. Cancer J (2015) 0.78
Monocyte-derived macrophage assisted breast cancer cell invasion as a personalized, predictive metric to score metastatic risk. Sci Rep (2015) 0.78
A bioavailable cathepsin S nitrile inhibitor abrogates tumor development. Mol Cancer (2016) 0.78
Dequalinium blocks macrophage-induced metastasis following local radiation. Oncotarget (2015) 0.78
A bladder cancer microenvironment simulation system based on a microfluidic co-culture model. Oncotarget (2015) 0.78
The role of tumor microenvironment in therapeutic resistance. Oncotarget (2016) 0.78
Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med (2016) 0.77
Photodynamic quenched cathepsin activity based probes for cancer detection and macrophage targeted therapy. Theranostics (2015) 0.77
Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells. Mol Cell Proteomics (2015) 0.77
Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3. Cell Rep (2016) 0.76
Cathepsin Protease Controls Copper and Cisplatin Accumulation via Cleavage of the Ctr1 Metal-binding Ectodomain. J Biol Chem (2016) 0.76
Selective targeting of tumor and stromal cells by a nanocarrier system displaying lipidated cathepsin B inhibitor. Angew Chem Int Ed Engl (2014) 0.76
Lysosomal protein turnover contributes to the acquisition of TGFβ-1 induced invasive properties of mammary cancer cells. Mol Cancer (2015) 0.76
Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy. J Cancer Res Clin Oncol (2014) 0.76
Proteolytic characteristics of cathepsin D related to the recognition and cleavage of its target proteins. PLoS One (2013) 0.76
Microenvironment: Protective surroundings. Nat Rev Cancer (2011) 0.75
Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. Oncoimmunology (2017) 0.75
Macrophages as Key Drivers of Cancer Progression and Metastasis. Mediators Inflamm (2017) 0.75
Mesenchymal stem cells with Sirt1 overexpression suppress breast tumor growth via chemokine-dependent natural killer cells recruitment. Sci Rep (2016) 0.75
Resistin potentiates chemoresistance and stemness of breast cancer cells: Implications for racially disparate therapeutic outcomes. Cancer Lett (2017) 0.75
Nurse-like cells promote CLL survival through LFA-3/CD2 interactions. Oncotarget (2016) 0.75
Iron imaging reveals tumor and metastasis macrophage hemosiderin deposits in breast cancer. PLoS One (2017) 0.75
Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents. Cell Rep (2017) 0.75
Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy. Biomaterials (2017) 0.75
Cysteine protease cathepsin B mediates radiation-induced bystander effects. Nature (2017) 0.75
Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis. Proc Natl Acad Sci U S A (2017) 0.75
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol (1992) 12.96
Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol (2003) 8.61
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer (2006) 5.06
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 4.38
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev (2010) 3.56
Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest (2000) 3.47
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol (2004) 3.40
A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging (2004) 3.07
Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity (1999) 3.01
Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem Biol (2000) 2.84
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev (2006) 2.74
Specialized roles for cysteine cathepsins in health and disease. J Clin Invest (2010) 2.69
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res (2002) 2.69
Pericytes limit tumor cell metastasis. J Clin Invest (2006) 2.55
Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis (2005) 2.52
Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci U S A (1999) 2.48
Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A (2010) 2.19
Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J (2000) 2.09
Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci (2007) 2.07
Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res (2010) 1.84
Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem Biol (2000) 1.62
Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A (2010) 1.60
Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem (2008) 1.43
Tissue culture studies on pleural effusions from breast carcinoma patients. Cancer Res (1974) 1.42
Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol (2007) 1.36
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res (2008) 1.29
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res (2004) 1.27
Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res (2007) 1.24
Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development. Oncogene (2011) 1.18
Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets (2006) 1.17
Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci (2010) 1.16
Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res (1994) 1.15
Dissecting variability in responses to cancer chemotherapy through systems pharmacology. Clin Pharmacol Ther (2010) 1.11
Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer. Biol Chem (2010) 1.06
Allograft inflammatory factor-1/Ionized calcium-binding adapter molecule 1 is specifically expressed by most subpopulations of macrophages and spermatids in testis. Cell Tissue Res (2007) 1.06
Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther (2008) 1.04
Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem (2008) 0.98
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev (2010) 3.56
Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell (2013) 3.33
Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol (2010) 2.97
ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A (2007) 2.85
The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell (2012) 2.84
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev (2006) 2.74
Non-cell-autonomous tumor suppression by p53. Cell (2013) 2.40
The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg (2010) 2.26
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle (2007) 2.10
Proteolytic networks in cancer. Trends Cell Biol (2011) 2.10
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) (2011) 2.09
Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci (2007) 2.07
Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J (2005) 2.04
Breast imaging: understanding how accuracy is measured when lesions are the unit of analysis. Breast J (2012) 1.98
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol (2008) 1.75
Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical follow-up. Am J Surg Pathol (2011) 1.68
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res (2010) 1.67
Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res (2006) 1.56
Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One (2008) 1.55
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res (2006) 1.55
Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem (2008) 1.43
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst (2013) 1.42
A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol (2012) 1.39
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther (2009) 1.39
Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. J Neurosci (2009) 1.38
Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol (2011) 1.34
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res (2008) 1.25
Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res (2007) 1.24
mTOR regulates phagosome and entotic vacuole fission. Mol Biol Cell (2013) 1.22
Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle (2010) 1.22
Desmoid tumors (fibromatoses) of the breast: a 25-year experience. Ann Surg Oncol (2007) 1.21
Cathepsin-mediated necrosis controls the adaptive immune response by Th2 (T helper type 2)-associated adjuvants. J Biol Chem (2013) 1.20
FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol (2012) 1.18
Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One (2013) 1.18
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer (2003) 1.15
Intra- and interobserver variability in CT measurements in oncology. Radiology (2013) 1.14
Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer (2012) 1.11
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci U S A (2003) 1.07
Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer. Biol Chem (2010) 1.06
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol (2012) 1.06
Promoting professionalism through an online professional development portfolio: successes, joys, and frustrations. Acad Med (2007) 1.05
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol (2011) 1.03
Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases. Chem Biol (2007) 1.02
Myxofibrosarcoma: prevalence and diagnostic value of the "tail sign" on magnetic resonance imaging. Skeletal Radiol (2013) 1.01
The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep (2011) 1.00
Radioactive seed localization with 125I for nonpalpable lesions prior to breast lumpectomy and/or excisional biopsy: methodology, safety, and experience of initial year. Health Phys (2013) 1.00
Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma. Am J Surg Pathol (2010) 0.96
Fine-needle aspiration cytology of mammary adenomyoepithelioma: a study of 12 patients. Cancer (2006) 0.96
Safety and efficacy of radioactive seed localization with I-125 prior to lumpectomy and/or excisional biopsy. Eur J Radiol (2013) 0.96
Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol (2012) 0.96
Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol (2009) 0.95
Non-mammary metastases to the breast and axilla: a study of 85 cases. Mod Pathol (2012) 0.94
Cadherin-catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Res Treat (2011) 0.94
Detecting and exploiting etiologic heterogeneity in epidemiologic studies. Am J Epidemiol (2012) 0.94
Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol (2012) 0.94
Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma. Hum Pathol (2006) 0.92
Do characteristics of pulmonary nodules on computed tomography in children with known osteosarcoma help distinguish whether the nodules are malignant or benign? J Pediatr Surg (2011) 0.92
Emergence of spatial structure in the tumor microenvironment due to the Warburg effect. Proc Natl Acad Sci U S A (2013) 0.90
Carcinoid tumorlets simulate pulmonary metastases in women with breast cancer. Hum Pathol (2006) 0.89
Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. Mod Pathol (2013) 0.88
Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer (2012) 0.88
Does the benefit of sentinel node frozen section vary between patients with invasive duct, invasive lobular, and favorable histologic subtypes of breast cancer? Ann Surg (2008) 0.88
Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. Breast Cancer Res Treat (2012) 0.88
Tumour-host interactions: implications for developing anti-cancer therapies. Expert Rev Mol Med (2006) 0.87
Hepatic pedicle clamping during hepatic resection for colorectal liver metastases: no impact on survival or hepatic recurrence. Ann Surg Oncol (2012) 0.87
Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer (2009) 0.86
A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med (2013) 0.86
Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie (2010) 0.85
Distinguishing benign thymic lesions from early-stage thymic malignancies on computed tomography. J Thorac Oncol (2013) 0.85
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clin Exp Metastasis (2011) 0.84
In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. J Med Chem (2014) 0.82
Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole. J Surg Res (2011) 0.82
Microenvironment-mediated resistance to anticancer therapies. Cell Res (2012) 0.82
Aberrant E-cadherin staining patterns in invasive mammary carcinoma. World J Surg Oncol (2005) 0.81
Ductal carcinoma in situ: morphology-based knowledge and molecular advances. Adv Anat Pathol (2013) 0.80
Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma. Immunotherapy (2014) 0.80
Chimeric Antigen Receptor T Cells in Myeloma. N Engl J Med (2016) 0.80
Challenges in the interpretation of breast core biopsies. Breast J (2010) 0.80
Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. J Nucl Med (2013) 0.79
Synchronous breast cancers with different morphologic and molecular phenotypes occurring in Lynch syndrome: what does the heterogeneity imply? Am J Surg Pathol (2011) 0.79
Should breast density influence patient selection for breast-conserving surgery? Ann Surg Oncol (2012) 0.79
DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors. Am J Surg Pathol (2012) 0.79
Interobserver agreement for detection of malignant features of intraductal papillary mucinous neoplasms of the pancreas on MDCT. AJR Am J Roentgenol (2014) 0.78
Radial Scar at Image-guided Needle Biopsy: Is Excision Necessary? Am J Surg Pathol (2015) 0.78
Impact of margin assessment method on positive margin rate and total volume excised. Ann Surg Oncol (2013) 0.78
Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One (2013) 0.77
Primary lymphoma of the breast: a case of marginal zone B-cell lymphoma. Am Surg (2004) 0.77